Index Entries

Eric J. Lenze, Caline Mattar, Charles F. Zorumski, Angela Stevens, Julie Schweiger, Ginger E. Nicol, J. Philip Miller, Lei Yang, Michael Yingling, Michael S. Avidan, and Angela M. Reiersen
November 12, 2020
JAMA (Journal of the American Medical Association)
Washington University in St Louis

Findings: In this randomized trial that included 152 adult outpatients with confirmed COVID-19 and symptom onset within 7 days, clinical deterioration occurred in 0 patients treated with fluvoxamine vs 6 (8.3%) patients treated with placebo over 15 days, a difference that was statistically significant.”

document
COVID-19,fluvoxamine,medical treatments,pharmaceuticals